The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Open accessAbstract
Introduction: Cerebrospinal fluid analysis and other measurements of amyloidosis, such as amyloid‐binding positron emission tomography studies, are limited by cost and availability. There is a need for a more practical amyloid β (Aβ) biomarker for central nervous system amyloid deposition. Methods: We adapted our previously reported stable isotope labeling kinetics protocol to analyze the turnover kinetics and concentrations of Aβ38, Aβ40, and Aβ42 in human plasma. Results: Aβ isoforms have a half‐life of approximately 3 hours in plasma. Aβ38 demonstrated faster turnover kinetics compared with Aβ40 and Aβ42. Faster fractional turnover of Aβ42 relative to Aβ40 and lower Aβ42 and Aβ42/Aβ40 concentrations in amyloid‐positive participants were observed. Discussion: Blood plasma Aβ42 shows similar amyloid‐associated alterations as we have previously reported in cerebrospinal fluid, suggesting a blood‐brain transportation mechanism of Aβ. The stability and sensitivity of plasma Aβ measurements suggest this may be a useful screening test for central nervous system amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“an 8-year follow-up study of 599 volunteers (average age 70 years) in Australia found that cognitively normal PET amyloid-positive people had an elevated risk of developing Alzheimer's disease compared with amyloid negative (17·7% vs 8·1%; OR 2·4, 95% CI 1·5–4·0).184”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma Aβ measures now show promise [202,203].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [202]
The cited source says what the claim attributes to it.
In the citing paper
“While imaging/CSF biomarker data on subsets of individuals from well-designed community-based cohorts would provide additional research value, incorporating biomarkers on a large scale in many settings will require low-cost and minimally invasive biomarkers (e.g., blood or saliva) that are now emerging [202–205].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [202]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Over 80% of the 266 people who were PET amyloid-positive did not go onto develop a cognitive impairment within 8 years, showing positive status does not predict impairment for most people in a timeframe that might be a useful prognostic window.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Follow-up at 5 years of amyloid-positive participants with normal cognition or mild cognitive impairment versus amyloid negative people found the same pattern of increased risk (2·6, 1·4–4·9).”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Risk also increases per 1 year of age (HR 1·05, 95% CI 0·55–2·0/year), and APOEε4 status (2·6, 1·4–5·0).184”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measuredIn the citing paper
“Blood biomarkers for the presymptomatic phase of Alzheimer’s disease are largely lacking, although recent progress in the analysis of amyloid-β, tau, and neurofilament light chain (NfL) in the blood have been reported5–10.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [8]
In the citing paper
“Recent studies demonstrate the ability to detect CNS Aβ deposition via the use of plasma assessment of Aβ species”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Ovod et al., 2017
In the citing paper
“Most recently, 2 independent groups demonstrated improved accuracy for plasma Aβ42/Aβ40 using immunoprecipitation–mass spectrometry assays.19,20”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [20]
In the citing paper
“In mass spectrometry–based techniques, 2 recent studies have provided overall better accuracies for plasma Aβ42/Aβ40 (AUC, 0.84-0.97 depending on population and reference standard).19,20”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“3%, respectively, when confirmed by postmortem histopathology [4].”
BackgroundLRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Self-citationAge but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M. K., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 258
Cited by
Sorted by citations
Items 101–200 of 586
Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
Thijssen, E. H., Verberk, I. M. W., Kindermans, J., Abramian, A., Vanbrabant, J., Ball, A. J., Pijnenburg, Y. A. L., Lemstra, A. W., van der Flier, W. M., Stoops, E., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12285 · Cited by 89
Thijssen, E. H., Verberk, I. M. W., Vanbrabant, J., Koelewijn, A., Heijst, H., Scheltens, P., van der Flier, W. M., Vanderstichele, H., Stoops, E., & Teunissen, C. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-89004-x · Cited by 85
Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
Startin, C. M., Ashton, N. J., Hamburg, S., Hithersay, R., Wiseman, F. K., Mok, K. Y., Hardy, J., Lleó, A., Lovestone, S., Parnetti, L., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0477-0 · Cited by 87
Acute sleep loss decreases CSF‐to‐blood clearance of Alzheimer's disease biomarkers
Liu, H., Barthélemy, N. R., Ovod, V., Bollinger, J. G., He, Y., Chahin, S. L., Androff, B., Bateman, R. J., & Lucey, B. P. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12930 · Cited by 89
Self-citationNeurofilaments in disease: what do we know?
Gordon, B. A. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.02.001 · Cited by 82
Relevance of biomarkers across different neurodegenerative diseases
Ehrenberg, A. J., Khatun, A., Coomans, E. M., Betts, M. J., Capraro, F., Thijssen, E. H., Senkevich, K. A., Bharucha, T., Jafarpour, M., Young, P. N. E., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00601-w · Cited by 81
A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders
Manzano, S., Agüera, L., Aguilar, M., & Olazarán, J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00614 · Cited by 82
Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Milà‐Alomà, M., Suárez‐Calvet, M., & Molinuevo, J. L. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419888819 · Cited by 81
Tosun, D., Veitch, D. P., Aisen, P. S. S., Jack, C. R., Jagust, W. J., Petersen, R. C., Saykin, A. J., Bollinger, J., Ovod, V., Mawuenyega, K. G., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab008 · Cited by 86
Self-citationModeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming
Sun, Z., Kwon, J.-S., Ren, Y., Chen, S., Walker, C. K., Lu, X., Cates, K., Karahan, H., Sviben, S., Fitzpatrick, J. A. J., et al. (2024) · Science · doi:10.1126/science.adl2992 · Cited by 77
Self-citationKorecka, M., & Shaw, L. M. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15465 · Cited by 82
Benedet, A. L., Ashton, N. J., Pascoal, T. A., Leuzy, A., Mathotaarachchi, S. S., Kang, M. S., Therriault, J., Savard, M., Chamoun, M., Schöll, M., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.002 · Cited by 75
Xiao, Z., Wu, X. Y., Wu, W., Yi, J., Liang, X., Ding, S., Zheng, L., Luo, J., Gu, H., Zhao, Q., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00864-x · Cited by 75
Update on Biomarkers For Amyloid Pathology in Alzheimer’s Disease
Ashton, N. J., Schöll, M., Heurling, K., Gkanatsiou, E., Portelius, E., Höglund, K., Brinkmalm, G., Hye, A., Blennow, K., & Zetterberg, H. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0433 · Cited by 78
Shi, L., Westwood, S., Baird, A. L., Winchester, L. M., Dobričić, V., Kilpert, F., Hong, S., Franke, A., Hye, A., Ashton, N. J., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.4951 · Cited by 70
Ghahremani, M., Wang, M., Chen, H., Zetterberg, H., Smith, E. E., Ismail, Z., & Initiative, A. D. N. (2022) · Neurology · doi:10.1212/wnl.0000000000201517 · Cited by 75
Mattke, S., Cho, S. K., Bittner, T., Hlávka, J. P., & Hanson, M. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12081 · Cited by 73
Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force
Cummings, J. L., Blennow, K., Johnson, K. A., Keeley, M. B., Bateman, R. J., Molinuevo, J. L., Touchon, J., Aisen, P. S. S., & Vellas, B. J. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.14 · Cited by 72
Self-citationToden, S., Zhuang, J., Acosta, A. D., Karns, A. P., Salathia, N. S., Brewer, J. B., Wilcock, D. M., Aballi, J., Nerenberg, M. I., Quake, S. R., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb1654 · Cited by 72
Lleó, A., Zetterberg, H., Pegueroles, J., Karikari, T. K., Carmona-Iragui, M., Ashton, N. J., Montal, V., Barroeta, I., Lantero-Rodríguez, J., Videla, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24319-x · Cited by 72
Surface-functionalized SERS platform for deep learning-assisted diagnosis of Alzheimer's disease
Kim, M., Huh, S., Park, H. J., Cho, S. H., Lee, M., Jo, S., & Jung, Y. S. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116128 · Cited by 72
Optical nanomaterial-based detection of biomarkers in liquid biopsy
Kim, Y. J., Rho, W., Park, S.-M., & Jun, B. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01531-y · Cited by 77
Chatterjee, P., Zetterberg, H., Goozee, K. G., Lim, C. K., Jacobs, K. R., Ashton, N. J., Hye, A., Pedrini, S., Sohrabi, H. R., Shah, T. M., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1567-4 · Cited by 70
Zeng, X., Chen, Y., Sehrawat, A., Lee, J., Lafferty, T. K., Kofler, J., Berman, S., Sweet, R. A., Tudorascu, D., Klunk, W. E., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00711-1 · Cited by 79
Shi, Y., Lu, X., Zhang, L., Shu, H., Gu, L., Wang, Z., Gao, L., Zhu, J., Zhang, H., Zhou, D., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00095 · Cited by 67
d’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 71
Enhancing Top-Down Proteomics of Brain Tissue with FAIMS
Fulcher, J. M., Makaju, A., Moore, R. J., Zhou, M., Bennett, D. A., De Jager, P. L., Qian, W.-J., Paša-Tolić, L., & Petyuk, V. A. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00049 · Cited by 68
Sharma, A., Pachauri, V., & Flora, S. J. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01247 · Cited by 67
Palmqvist, S., Insel, P. S., Zetterberg, H., Blennow, K., Brix, B., Stomrud, E., Initiative, T. A. D. N., study, T. S. B., Mattsson, N., & Hansson, O. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.014 · Cited by 65
Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
Mankhong, S., Kim, S., Lee, S., Kwak, H., Park, D., Joa, K., & Kang, J. (2022) · Biomedicines · doi:10.3390/biomedicines10040850 · Cited by 72
Fichou, Y., Al‐Hilaly, Y. K., Devred, F., Smet‐Nocca, C., Tsvetkov, P. O., Verelst, J., Winderickx, J., Geukens, N., Vanmechelen, E., Perrotin, A., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0682-x · Cited by 67
Bateman, R. J., Blennow, K., Doody, R. S., Hendrix, S. B., Lovestone, S., Salloway, S., Schindler, R. J., Weiner, M. W., Zetterberg, H., Aisen, P. S. S., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.21 · Cited by 62
Self-citationPlasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment
Chen, T., Lee, Y.-J., Lin, S.-Y., Chen, J.-P., Hu, C., Wang, P., & Cheng, I. H.-J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50315-9 · Cited by 67
Stockmann, J., Verberk, I. M. W., Timmesfeld, N., Denz, R., Budde, B., Lange-Leifhelm, J., Scheltens, P., van der Flier, W. M., Nabers, A., Teunissen, C. E., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00738-8 · Cited by 62
Zicha, S., Bateman, R. J., Shaw, L. M., Zetterberg, H., Bannon, A. W., Horton, W. A., Baratta, M., Kolb, H. C., Dobler, I., Mordashova, Y., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12697 · Cited by 58
Self-citationShahpasand‐Kroner, H., Klafki, H.-W., Bauer, C., Schuchhardt, J., Hüttenrauch, M., Stazi, M., Bouter, C., Wirths, O., Vogelgsang, J. S., & Wiltfang, J. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0448-x · Cited by 61
Bateman, R. J., Li, Y., McDade, E., Llibre‐Guerra, J. J., Clifford, D. B., Atri, A., Mills, S. L., Santacruz, A. M., Wang, G., Supnet, C. B., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00024-9 · Cited by 71
Self-citationSILK studies — capturing the turnover of proteins linked to neurodegenerative diseases
Paterson, R. W., Gabelle, A., Lucey, B. P., Barthélemy, N. R., Leckey, C. A., Hirtz, C., Lehmann, S., Sato, C., Patterson, B. W., West, T., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0222-0 · Cited by 60
Self-citationZetterberg, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12618 · Cited by 59
Tau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patients
Smith, R., Cullen, N. C., Pichet Binette, A., Leuzy, A., Blennow, K., Zetterberg, H., Klein, G., Borroni, E., Ossenkoppele, R., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12875 · Cited by 60
Cilento, E. M., Jin, L., Stewart, T., Shi, M., Sheng, L., & Zhang, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14635 · Cited by 60
Fluid biomarkers in Alzheimer's disease
Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2022.09.006 · Cited by 58
Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer’s disease
Zhang, B., Zhang, C., Wang, Y., Chen, L., Qiao, Y., Wang, Y., Peng, D., & Initiative, A. D. N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1150510 · Cited by 58
Kang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64
Shen, X., Li, J., Wang, H., Li, H., Huang, Y., Yang, Y., Tan, L., Dong, Q., Yu, J., & Initiative, A. D. N. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12104 · Cited by 57
Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics
Dhauria, M., Mondal, R., Deb, S., Shome, G., Chowdhury, D., Sarkar, S., & Benito‐León, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010911 · Cited by 62
The AB255 Study Group, Pérez‐Grijalba, V., Arbizu, J., Romero, J., Prieto, E., Pesini, P., Sarasa, L., Guillén, F., Monleón, I., José, I. S., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0549-1 · Cited by 60
Biomarkers of Alzheimer Disease
Budelier, M. M., & Bateman, R. J. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.030080 · Cited by 59
Self-citationComparison of plasma and CSF biomarkers in predicting cognitive decline
Aschenbrenner, A. J., Li, Y., Henson, R. L., Volluz, K., Hassenstab, J. J., Verghese, P. B., West, T., Meyer, M. R., Kirmess, K. M., Fagan, A. M., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51670 · Cited by 59
Self-citationMethods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias
Teunissen, C. E., Kimble, L. E., Bayoumy, S., Bolsewig, K., Burtscher, F., Coppens, S., Das, S., Gogishvili, D., Gomes, B. F., José, N. G. D. S., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100629 · Cited by 61
Budelier, M. M., He, Y., Barthélemy, N. R., Jiang, H., Li, Y., Park, E., Henson, R. L., Schindler, S. E., Holtzman, D. M., & Bateman, R. J. (2022) · Brain Communications · doi:10.1093/braincomms/fcac045 · Cited by 55
Self-citationBlood biomarkers for Alzheimer's disease and related disorders
Zetterberg, H., & Schott, J. M. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13628 · Cited by 55
Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges
Delaby, C., Hirtz, C., & Lehmann, S. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.09.003 · Cited by 60
Ding, M., Ding, S., Du, D., Wang, X., Hu, X., Guan, P., Lyu, Z., & Lin, Y. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117087 · Cited by 56
Supraja, P., Tripathy, S., Singh, R., Singh, V., Chaudhury, G., & Singh, S. G. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113294 · Cited by 53
Impact of pre‐analytical sample handling factors on plasma biomarkers of Alzheimer's disease
Kurz, C., Stöckl, L., Schrurs, I., Suridjan, I., Guersel, S., Bittner, T., Jethwa, A., & Perneczky, R. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15757 · Cited by 51
Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individuals
Ferreira, P. C. L., Therriault, J., Tissot, C., Ferrari‐Souza, J. P., Benedet, A. L., Povala, G., Bellaver, B., Leffa, D. T., Brum, W. S., Lussier, F. Z., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13393 · Cited by 53
Obrocki, P., Khatun, A., Ness, D., Senkevich, K. A., Hanrieder, J., Capraro, F., Mattsson, N., Andréasson, U., Portelius, E., Ashton, N. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00586-6 · Cited by 51
Hampel, H. J., Vergallo, A., Caraci, F., Cuello, A. C., Lemercier, P., Vellas, B. J., Giudici, K. V., Baldacci, F., Hänisch, B., Haberkamp, M., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108081 · Cited by 52
NAKAI, T., Yamada, K., & Mizoguchi, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115549 · Cited by 53
Chatterjee, P., Elmi, M., Goozee, K. G., Shah, T. M., Sohrabi, H. R., Dias, C. B., Pedrini, S., Shen, K., Asih, P. R., Dave, P., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190533 · Cited by 50
Molecular Imaging Approaches in Dementia
Villemagne, V. L., Barkhof, F., Garibotto, V., Landau, S. M., Nordberg, A. K., & van Berckel, B. N. M. (2021) · Radiology · doi:10.1148/radiol.2020200028 · Cited by 56
Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases
Seino, Y., Nakamura, T., Kawarabayashi, T., Hirohata, M., Narita, S., Wakasaya, Y., Kaito, K., Ueda, T., Harigaya, Y., & Shoji, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181152 · Cited by 50
Nabers, A., Hafermann, H., Wiltfang, J., & Gerwert, K. B. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.008 · Cited by 47
The global Alzheimer's Association round robin study on plasma amyloid β methods
Pannee, J., Shaw, L. M. J., Korecka, M., Waligórska, T., Teunissen, C. E., Stoops, E., Vanderstichele, H., Mauroo, K., Verberk, I. M. W., Keshavan, A., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12242 · Cited by 48
Self-citationPlasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer’s Disease
Lim, Y. Y., Maruff, P. T., Kaneko, N., Doecke, J. D., Fowler, C. J., Villemagne, V. L., Kato, T., Rowe, C. C., Arahata, Y., Iwamoto, S., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200475 · Cited by 48
Advances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 48
Veerabhadrappa, B., Delaby, C., Hirtz, C., Vialaret, J., Alcolea, D. A., Lleó, A., Fortea, J., Santosh, M. S., Choubey, S., & Lehmann, S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1678011 · Cited by 49
Day, G. S. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001089 · Cited by 47
Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update
Park, S. A., Jang, Y. J., Kim, M. K., Lee, S. M., & Moon, S. Y. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.4.401 · Cited by 47
Dokholyan, N. V., Mohs, R. C., & Bateman, R. J. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12330 · Cited by 47
Self-citationBiomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 52
Blennow, K., & Zetterberg, H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.006 · Cited by 46
Gao, F., Dai, L., Wang, Q., Liu, C., Deng, K., Cheng, Z., Lv, X., Wu, Y., Zhang, Z., Tao, Q., et al. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.07.009 · Cited by 46
Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
Ashton, N. J., Suárez‐Calvet, M., Heslegrave, A., Hye, A., Razquín, C., Pástor, P., Sánchez‐Valle, R., Molinuevo, J. L., Visser, P. J., Blennow, K., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0545-5 · Cited by 45
Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression
Nho, K. T., Kueider‐Paisley, A., Arnold, M., MahmoudianDehkordi, S., Risacher, S. L., Louie, G., Blach, C., Baillie, R., Han, X., Kastenmüller, G., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab139 · Cited by 46
Genetic risk factors for Alzheimer disease: emerging roles of microglia in disease pathomechanisms
Takatori, S., Wang, W., Iguchi, A., & Tomita, T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_5 · Cited by 44
A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer’s Disease
Xu, C., Zhao, L., & Dong, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220673 · Cited by 46
Chen, Y.-R., Liang, C., Chu, H., Voss, J. G., Kang, X. L., O’Connell, G. C., Jen, H., Liu, D., Hsiao, S. S., & Chou, K. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101446 · Cited by 42
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 55
Amyloid-β as a Blood Biomarker for Alzheimer’s Disease: A Review of Recent Literature
Wang, X., Sun, Y., Li, T., Cai, Y., & Han, Y. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190714 · Cited by 41
Combining blood-based biomarkers to predict risk for Alzheimer’s disease dementia
Schindler, S. E., & Bateman, R. J. (2021) · Nature Aging · doi:10.1038/s43587-020-00008-0 · Cited by 44
Self-citationAnother step forward in blood-based diagnostics for Alzheimer’s disease
Bateman, R. J., Barthélemy, N. R., & Horie, K. (2020) · Nature Medicine · doi:10.1038/s41591-020-0797-4 · Cited by 37
Self-citationTesting the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40
Self-citationQiang, Q., Skudder‐Hill, L., Toyota, T., Wei, W., & Adachi, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-20324-2 · Cited by 40
Jiao, F., Yi, F., Wang, Y., Zhang, S., Guo, Y., Du, W., Gao, Y., Ren, J., Zhang, H., Liu, L., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00212 · Cited by 40
Nanoconstructs as a versatile tool for detection and diagnosis of Alzheimer biomarkers
Gopalan, D., Pandey, A. P., Alex, A. T., Kalthur, G., Pandey, S., Udupa, N., & Mutalik, S. (2020) · Nanotechnology · doi:10.1088/1361-6528/abcdcb · Cited by 42
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status
Mofrad, R. B., Scheltens, P., Kim, S., Kang, S., Youn, Y. C., An, S. S. A., Tomassen, J., van Berckel, B. N. M., Visser, P. J., van der Flier, W. M., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00873-w · Cited by 42
Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease
Omar, S. H., & Preddy, J. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030063 · Cited by 39
Hu, Y., Cho, M., Sachdev, P., Dage, J., Hendrix, S., Hansson, O., Bateman, R. J., & Hampel, H. (2024) · Med · doi:10.1016/j.medj.2024.08.004 · Cited by 42
Self-citationBiofluid biomarkers in Alzheimer’s disease and other neurodegenerative dementias
Zetterberg, H., & Bendlin, B. B. (2026) · Nature · doi:10.1038/s41586-025-10018-w · Cited by 45
Pascual‐Lucas, M., Allué, J. A., Sarasa, L., Fandos, N., Castillo, S., Terencio, J. V., Sarasa, M., Tartari, J. P., Sanabria, Á., Tárraga, L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01143-z · Cited by 41
Using Alzheimer's disease blood tests to accelerate clinical trial enrollment
Schindler, S. E., Li, Y., Li, M., Despotis, A., Park, E., Vittert, L., Hamilton, B. H., Womack, K. B., Saef, B., Holtzman, D. M., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12754 · Cited by 38
Self-citationRaffin, J., Rolland, Y., Aggarwal, G., Nguyen, A. D., Morley, J. E., Li, Y., Bateman, R. J., Vellas, B. J., Barreto, P. D. S., MAPT/DSA Group, et al. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab094 · Cited by 40
Self-citationHanon, O., Vidal, J., Lehmann, S., Bombois, S., Allinquant, B., Rose, C., Tréluyer, J., Abdoul, H., Gelé, P., Delmaire, C., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12613 · Cited by 38
Biomarkers for Managing Neurodegenerative Diseases
Cheslow, L., Snook, A. E., & Waldman, S. A. (2024) · Biomolecules · doi:10.3390/biom14040398 · Cited by 41
Duan, S., Cai, T., Liu, F., Li, Y., Yuan, H., Yuan, W., Huang, K., Hoettges, K. F., Chen, M., Lim, E. G., et al. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.342575 · Cited by 37
Clinical use of biomarkers in the era of Alzheimer's disease treatments
VandeVrede, L. A., & Schindler, S. E. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14201 · Cited by 40
Stocker, H. R., Nabers, A., Perna, L., Möllers, T., Rujescu, D., Hartmann, A. M., Holleczek, B., Schöttker, B., Gerwert, K. B., & Brenner, H. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.08.189 · Cited by 36
Yamashita, K., Watanabe, S., Ishiki, K., Miura, M., Irino, Y., Kubo, T., Matsui, J., Hagino, K., Iwanaga, S., & Yoshida, T. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.066 · Cited by 37
Metadata
- Authors
- Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., Benzinger, T., Fagan, A. M., Patterson, B. W., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2017-07-19
- Volume
- 13
- Issue
- 8
- Pages
- 841-849
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC5567785
- OpenAlex
- W2736518852
- Cited by
- 585
- References
- 18
- Citations by year
- 2026: 44 · 2025: 44 · 2024: 74 · 2023: 65 · 2022: 84 · 2021: 85 · 2020: 70 · 2019: 66 · 2018: 47 · 2017: 2
- FWCI
- 37.40
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- MetLife Foundation
- AbbVie
- Amgen
- AstraZeneca
- Biogen
- Eisai
- Pfizer
- Sanofi
- Avid Radiopharmaceuticals
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta, plasma amyloid-beta
- MeSH terms
- Aged, Amyloidosis, Chromatography, Liquid, Humans, Isotope Labeling, Kinetics, Peptide Fragments, Prospective Studies, ROC Curve, Mass Spectrometry, Biomarkers, Single-Blind Method, Amyloid beta-Peptides, Area Under Curve, Immunoprecipitation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
